Sec Form 3/A Filing - DCVC Bio, L.P. @ AbCellera Biologics Inc. - 2020-12-11

FORM 3/A Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person DCVC Bio, L.P. 2. Issuer Name and Ticker or Trading Symbol AbCellera Biologics Inc. [ ABCL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 270 UNIVERSITY AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 12/11/2020 (Street) PALO ALTO, CA94301 4. If Amendment, Date Original Filed (MM/DD/YY) 12/11/2020 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A1 Preferred Shares ( 1 ) ( 1 ) ( 1 ) Common Shares 21,052,640 I See footnote ( 2 ) ( 3 ) Series A2 Preferred Shares ( 1 ) ( 1 ) ( 1 ) Common Shares 8,023,710 I See footnote ( 2 ) ( 3 ) Convertible Note $ 17 ( 4 ) ( 4 ) Common Shares 29,411 I See footnote ( 2 ) ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other DCVC Bio, L.P. 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X DCVC Bio GP, LLC 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X ZNM Capital Management, LLC 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X Ocko Matthew 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X Stead Kiersten 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X Bogue Zachary 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X JNK Capital Management, LLC 270 UNIVERSITY AVENUE PALO ALTO, CA94301 X Signatures DCVC Bio, L.P. By: DCVC Bio GP, LLC Its: General Partner By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member 12/17/2020 Signature of Reporting Person Date DCVC Bio GP, LLC By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member 12/17/2020 Signature of Reporting Person Date ZNM Capital Management, LLC By: /s/ Matthew Ocko Matthew Ocko, Managing Member 12/17/2020 Signature of Reporting Person Date Matthew Ocko /s/ Matthew Ocko 12/17/2020 Signature of Reporting Person Date Kiersten Stead /s/ Kiersten Stead 12/17/2020 Signature of Reporting Person Date Zachary Bogue /s/ Zachary Bogue 12/17/2020 Signature of Reporting Person Date JNK Capital Management, LLC, By: /s/ Kiersten Stead Kiersten Stead, Managing Member 12/17/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Series A1 Preferred Shares and Series A2 Preferred Shares (collectively, the "Preferred Shares") are convertible into Common Shares at a 1:10 ratio into the number of Common Shares as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Preferred Shares have no expiration date. ( 2 )These securities are held by DCVC Bio, L.P. ("DCVC Bio"). DCVC Bio GP, LLC ("DCVC Bio GP") is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio. ( 3 )(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any. ( 4 )The convertible promissory note ("Convertible Note") has a maturity date of October 30, 2025 and the principal amount of the Convertible Note will convert upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share.

Remarks: This amendment is being filed to add certain Reporting Persons that were inadvertently not included on the Form 3 initially filed. The holdings reported in this amendment are not new or revised but are being reported to gain access to the SEC's EDGAR filing system.This is one of two Form 3s filed on the date hereof in respect of these securities. The Reporting Person for the other Form 3 is John Hamer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.